Do you know the identities of the companies developing CAR-T therapies worldwide?
CAR-T companies are on the rise, supported by growing investment flowing into CAR-T product development and landmark approvals of CAR-T cell therapies by the U.S. FDA, European Medicines Agency (EMA), Health Canada, Australian TGA, and others. There have also been major acquisitions within the CAR-T space, with Celgene snagging Juno Therapeutics for a shocking $9 billion in and Gilead acquiring Kite Pharma for an astounding $11.9 billion.
This is a global database of CAR-T companies that we originally developed for our own purposes.
Because more and more of our readers have been requesting access to it, we are making it accessible to the public – for a limited-time only.
Features of the CAR-T Company Database
Chimeric antigen receptors (CARs) are genetically engineered allogeneic cells that are developed in the laboratory and infused into a patient, to help in detecting and fighting cancer cells. The protein constructs stimulate anti-cancer T-cells which in turn boost a patient’s immune system.
The database features the following information for CAR-T market competitors:
- Company Name
- CAR-T Technology
- Disease Targets
- Description of CAR-T Involvement
- City / State
- Link to CAR-T Programs
- Company Website
Use it to:
- Identify global competitors within the CAR-T marketplace
- Quantify CAR-T products in late-stage development
- Reveal preclinical & clinical programs supporting CAR-T development
- Identify regions that are “hotspots” for CAR-T cell therapies
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
Creating the CAR-T Company Database
It took our team of analysts hours of exhaustive research to uncover these CAR-T cell therapy companies from across the globe. It required translating company sites and clinical trial programs from dozens of languages. Thankfully, we have a talented and multilingual team who was up to the task.
Because we continuously update this database to reflect new competitors entering the CAR-T cell therapy marketplace, we are confident it will be an invaluable resource to your group.
With the value of recent CAR-T IPO’s totaling nearly $1 billion, CAR-T financing rounds exceeding $950 million, and $20 billion of market capitalization from CAR-T companies in recent years, this is clearly a hot market segment.
Would you benefit from knowing the identities of CAR-T market competitors worldwide, as well as being informed about historic CAR-T funding events?
If so, you can claim the CAR-T database for only $49 and get the “CAR-T Funding Brief” for FREE (a $49 value).
Act now and both products will immediately be available for download, with printing rights allowed.
Of course, your investment is backed by our 60-Day Money Back Guarantee.